Curcumin Attenuates Doxorubicin-Induced Cardiac Oxidative Stress and Increases Survival in Mice
Authors:
- Felipe S. ArrudaFelipe S. Arruda
- Fernanda D. ToméFTFernanda D. Tomé
- Anália C. MilhomemAMAnália C. Milhomem
- Pablo I. R. FrancoPFPablo I. R. Franco
- Allisson B. JustinoAJAllisson B. Justino
- Rodrigo R. FrancoRFRodrigo R. Franco
- Erica C. CamposECErica C. Campos
- Foued S. EspindolaFoued S. Espindola
- Danilo F. SoaveDSDanilo F. Soave
- Mara Rubia N. CelesMara Rubia N. Celes
Open Access
- 22 August 2024
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (8) , 1105
Abstract
Doxorubicin (DOX) is a potent chemotherapeutic agent used to treat multiple types of cancer, but its clinical application is limited by cardiotoxicity, mainly due to oxidative stress. Curcumin (CUR) is a natural polyphenolic compound with strong antioxidant properties, but its potential protective effects against DOX-induced cardiotoxicity need further investigation. This study aimed to evaluate CUR’s efficacy in mitigating DOX-induced oxidative stress in the hearts of BALB/c mice. Mice received a DOX dose of 9 mg/kg or 16 mg/kg; half of the mice received daily doses of 100 mg/kg CUR for 15 days. Survival analysis, histopathological examination, and oxidative stress markers were assessed to determine the cardioprotective effects of CUR. Results showed that CUR significantly reduced oxidative damage and improved survival rates, particularly at the lower DOX dose (9 mg/kg). Mice treated with DOX-9 mg/kg plus CUR showed improved health conditions and reduced levels of reactive oxygen species (ROS), lipid peroxidation, sulfhydryl production, and protein carbonylation. Histopathological analysis confirmed reduced cardiac tissue damage. In conclusion, CUR combined with a lower dose of DOX effectively reduces oxidative stress and cardiac injury, enhancing survival in BALB/c mice. These findings suggest that CUR is a promising adjunct therapy to mitigate DOX-induced cardiotoxicity, potentially improving the DOX therapeutic index in cancer treatment.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de Goiás (201710267000068, 88881.845026/2023-01)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (201710267000068, 88881.845026/2023-01)
This publication has 46 references indexed in Scilit:
- Recent updates on clinical developments of curcumin and its derivativesPhytotherapy Research, 2023
- Curcumin and chemokines: mechanism of action and therapeutic potential in inflammatory diseasesInflammopharmacology, 2023
- A protective effect of curcumin on cardiovascular oxidative stress indicators in systemic inflammation induced by lipopolysaccharide in ratsBiochemistry and Biophysics Reports, 2021
- Curcumin ameliorates doxorubicin‐induced cardiotoxicity by abrogation of inflammation, apoptosis, oxidative DNA damage, and protein oxidation in ratsJournal of Biochemical and Molecular Toxicology, 2018
- Mode of treatment governs curcumin response on doxorubicin-induced toxicity in cardiomyoblastsMolecular and Cellular Biochemistry, 2017
- Allicin ameliorates doxorubicin-induced cardiotoxicity in rats via suppression of oxidative stress, inflammation and apoptosisCancer Chemotherapy and Pharmacology, 2017
- Cardioprotective mechanisms of phytochemicals against doxorubicin-induced cardiotoxicityBiomedicine & Pharmacotherapy, 2017
- Anthracycline Chemotherapy and CardiotoxicityCardiovascular Drugs and Therapy, 2017
- Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantroneArchives of Toxicology, 2016
- Adriamycin, 14‐hydroxydaimomycin, a new antitumor antibiotic from S. Peucetius var. caesiusBiotechnology and Bioengineering, 1969